MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award

Rhea-AI Filing Summary

MIRA PHARMACEUTICALS, INC. director Matthew Pratt received a grant of stock options as equity compensation. He was awarded 50,000 stock options for common stock at an exercise price of $0.94 per share, equal to the closing price on June 12, 2026.

The options were granted under the company’s 2022 Omnibus Incentive Plan. Half of the options vest six months after the grant date and the remaining half vest one year after the grant date. Following this award, the filing shows Pratt holding 50,000 stock options directly, which expire on June 12, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Whalen Matthew Pratt

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

Key Figures

Options granted: 50,000 options Exercise price: $0.94 per share Underlying shares: 50,000 shares +3 more

6 metrics

Options granted 50,000 options Stock options award to director on June 12, 2026

Exercise price $0.94 per share Equal to closing price on June 12, 2026

Underlying shares 50,000 shares Common stock underlying the options

Post-grant option holdings 50,000 options Total derivative securities following transaction

Expiration date June 12, 2036 Option term end date

Vesting schedule 50% at 6 months, 50% at 12 months From the June 12, 2026 grant date

Key Terms

Stock Options (right to buy), exercise price, 2022 Omnibus Incentive Plan, vesting, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"at an exercise price of $0.94 each"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2022 Omnibus Incentive Plan financial

"pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated"

vesting financial

"50% of the options vest on the six-month anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:00 PM Accepted by SEC EDGAR 06/15/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whalen Matthew Pratt

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.94(1)	06/12/2026		A		50,000		(2)	06/12/2036	Common Stock	50,000	$0	50,000(3)	D

Explanation of Responses:

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

	/s/ Matthew Pratt Whalen	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MIRA (MIRA) director Matthew Pratt report in this Form 4?

Director Matthew Pratt reported receiving 50,000 stock options for MIRA common stock as an equity award. The options were granted under the 2022 Omnibus Incentive Plan with an exercise price of $0.94 per share and long-dated expiration.

How many MIRA (MIRA) stock options were granted and at what price?

The filing shows a grant of 50,000 stock options with an exercise price of $0.94 per share. The exercise price equals the closing price of MIRA’s common stock on June 12, 2026, according to the footnotes.

When do Matthew Pratt’s MIRA (MIRA) stock options vest?

The options vest in two equal tranches. According to the disclosure, 50% of the 50,000 options vest on the six-month anniversary of the grant date and the remaining 50% vest on the one-year anniversary of the grant date.

When do the granted MIRA (MIRA) stock options expire?

The reported stock options expire on June 12, 2036. This long expiration gives the director a multi-year window to exercise the options once vested, subject to the terms of the 2022 Omnibus Incentive Plan.

Did the MIRA (MIRA) Form 4 show any stock sales or purchases?

The Form 4 only reports a grant of derivative securities, specifically 50,000 stock options, coded as an acquisition award. It does not show any open-market purchases or sales of MIRA common stock in this transaction.